{"issuance_frequency":"","notes_translated":{"fr":"Les organismes de réglementation des médicaments d'Australie, du Canada, de Singapour, de Suisse et du Royaume-Uni (Consortium Access) ont discuté des exigences réglementaires en matière de preuves pour l'autorisation des vaccins contre la COVID-19 et des considérations relatives à la pharmacovigilance après la mise sur le marché. Cette déclaration collective sur les vaccins contre la COVID-19 s'appuie sur l'engagement pris par le Consortium en mai 2020 de collaborer pour lutter contre la pandémie mondiale de COVID-19. ","en":"The medicine regulators from Australia, Canada, Singapore, Switzerland and the United Kingdom (Access Consortium) have discussed the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance. This collective statement on COVID-19 vaccines builds on the Consortium's May 2020 pledge to work together to counter the COVID-19 global pandemic. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"12d303b6-de17-41ed-ba14-67d1984197ad","metadata_created":"2021-06-30T17:46:19.042660","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-30T17:46:19.042667","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-30","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["coronavirus","COVID-19","vaccins","international","médicaments","médicaments","produits biologiques","Santé Canada"],"en":["coronavirus","COVID-19","vaccines","international","medications","drugs","biologics","Health Canada"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Déclaration du Consortium Access sur les preuves relatives aux vaccins contre la COVID-19","en":"Access Consortium statement on COVID-19 vaccines evidence"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"12d303b6-de17-41ed-ba14-67d1984197ad","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c70a3db9-08c0-47ad-9270-ea1186dcc3a4","related_relationship":"","name_translated":{"fr":"Déclaration du Consortium Access sur les preuves relatives aux vaccins contre la COVID-19","en":"Access Consortium statement on COVID-19 vaccines evidence"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Access Consortium statement on COVID-19 vaccines evidence","language":["en"],"created":"2021-06-30T17:46:19.141917","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/engaging-international-partners/access-statement-vaccine-evidence.html","last_modified":null,"position":0,"revision_id":"b1e724b4-8819-4840-8b28-6b6884d9e399","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"12d303b6-de17-41ed-ba14-67d1984197ad","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4161e3ec-1716-4848-ae95-6efba1d5a108","related_relationship":"","name_translated":{"fr":"Déclaration du Consortium Access sur les preuves relatives aux vaccins contre la COVID-19","en":"Access Consortium statement on COVID-19 vaccines evidence"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Access Consortium statement on COVID-19 vaccines evidence","language":["fr"],"created":"2021-06-30T17:46:19.141923","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/collaboration-partenaires-internationaux/declaration-access-preuves-vaccins.html","last_modified":null,"position":1,"revision_id":"b1e724b4-8819-4840-8b28-6b6884d9e399","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-01-21 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"12d303b6-de17-41ed-ba14-67d1984197ad","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The medicine regulators from Australia, Canada, Singapore, Switzerland and the United Kingdom (Access Consortium) have discussed the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance. This collective statement on COVID-19 vaccines builds on the Consortium's May 2020 pledge to work together to counter the COVID-19 global pandemic. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Access Consortium statement on COVID-19 vaccines evidence","revision_id":"b1e724b4-8819-4840-8b28-6b6884d9e399"}